Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Scleroderma Market Outlook

Thelansis’s “Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Scleroderma Overview

Scleroderma, a connective tissue disorder, primarily manifests as thickened and hardened skin. There are two main types: localized and systemic, also known as systemic sclerosis. In localized scleroderma, the condition primarily affects the skin and may also impact muscles and bones. The exact causes of scleroderma remain unclear, but some evidence suggests genetic and environmental factors play a role in its development. Silica and specific organic solvents are recognized risk factors for systemic scleroderma. These factors trigger an immune system response, damaging blood vessels and tissues and forming scar tissue and excess collagen accumulation. Raynaud’s phenomenon (RP) is often the initial symptom of scleroderma, sometimes appearing years before other signs of the disease. It is a visible expression of a systemic vascular issue fundamental to scleroderma’s development. Three primary mechanisms contribute to scleroderma development: vascular anomalies, excess fibrosis, and autoimmune processes. Abnormal interactions between endothelial cells, fibroblasts, and lymphocytes (B and T) lead to microcirculatory vascular involvement. This results in the production of endothelin by endothelial cells, causing vasoconstriction and fibroblast activation. Additionally, fibroblasts and activated endothelial cells produce reactive oxygen species, accelerating vascular remodeling and the obliteration of small vessels. Activated fibroblasts quickly transform into myofibroblasts, which have an increased ability to synthesize collagen. Several other conditions exhibit skin changes similar to scleroderma, including Scleredema (scleredema diabeticorum and scleredema of Buschke), Eosinophilic fasciitis, Eosinophilia-myalgia syndrome, and Nephrogenic systemic fibrosis. The life expectancy of systemic sclerosis patients depends on the extent and severity of internal organ involvement. Compared to healthy individuals of the same age, those with SSc have a 3.5 times higher mortality rate. Survival rates for SSc patients are approximately 75-80% after five years, 55% after ten years, 35-40% after 15 years, and 25-30% after 20 years. Risk factors for higher mortality include older age at diagnosis, male gender, diffuse skin involvement, and organ involvement (such as pulmonary, cardiac, or renal). Systemic scleroderma’s skin hardening and musculoskeletal effects, especially in the hands, can lead to functional disabilities. Oral restrictions can affect food intake and dental care. Linear scleroderma of the limbs, especially when it affects underlying bones, can also cause functional issues and potential aesthetic concerns in cases of “en coup de sabre” linear scleroderma. Treatment for scleroderma aims to alleviate symptoms and slow disease progression, although there is no single proven agent to modify the course of the disease.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034